Aalto Bio Reagents Yellow Fever Monoclonal Antibodies

Jan 31, 2017

Aalto Bio Reagents announced the availability of its yellow fever monoclonal antibodies for diagnostic test manufacturers, vaccine developers, and researchers globally. The monoclonal antibodies are raised against cell-culture derived viral lysate from strain 17D. The yellow fever antibodies complement the firm's portfolio of recombinant proteins and antibodies for chikungunya, dengue, and Zika virus diagnostic tests.

More Like This

Sep 22, 2017

ProteinSimple 32x4 Simple Plex cartridge

Bio-Techne brand ProteinSimple launched its 32x4 Simple Plex cartridge for the Ella immunoassay platform. The cartridge simultaneously measures up to 32 different samples, such as serum, plasma, and cell culture supernatants, against four different analytes of interest. It doubles the current sample throughput while maintaining a total immunoassay time of 85 minutes, ProteinSimple said, adding it comes preloaded with analyte-specific capture and detection antibodies, and detection reagents. 

Sep 20, 2017

Blueprint Genetics Whole Exome Sequencing

Blueprint Genetics is now offering whole-exome sequencing to customers in the US. The assay has a minimum mean coverage of 100-fold. On average, 98.9 percent of gene-coding regions, captured with Agilent SureSelect V6, are covered at least 15-fold. The company confirms all clinically relevant variants by Sanger sequencing and its interpretation team includes clinical experts. Turnaround time for the assay, which comes in different versions, is six to nine weeks.

Sep 19, 2017

ARUP Laboratories/IDbyDNA Explify Respiratory

ARUP Laboratories and IDbyDNA have launched Explify Respiratory, a next-generation sequencing-based test for respiratory infections. Explify Respiratory detects more than 200 common and rare bacterial, fungal, and viral respiratory pathogens with a single test. It is powered by IDbyDNA's Taxonomer software, a DNA search engine that can rapidly identify any organism by its genetic material. The test is the first in a line of tests that ARUP Labs and IDbyDNA plan to launch as part of a previously announced strategic partnership to develop and commercialize infectious disease testing using metagenomics.

Sep 14, 2017

Qnostics ME Evaluation Panel

Qnostics launched the ME Evaluation Panel for meningitis/encephalitis evaluation. It consists of 14 controls for the qualitative detection of bacterial, viral, and fungal targets, including Neisseria meningitidis, Haemophilus influenzae, Escherichia coli K1, and others. The panel can be used to independently monitor each target and all phases of the testing process, Qnostics said, adding it was designed with known performance on the BioFire FilmArray platform. 

Sep 13, 2017

Phosphorous Ophthalmology, Drug Response Test

Computational genomics firm Phosphorus launched a test for inherited conditions associated with vision loss and blindness, and a pharmacogenomic test to assess the efficacy of various drugs based on their genetic makeup. The ophthalmology genetic test covers retinal disorders, cataracts, glaucoma, and corneal dystrophy. The drug response test covers cardiology, psychiatry, oncology, pain management, neurology, immunology. gastroenterology, repiratory, infectious disease, and others. 

Sep 13, 2017

Variantyx Unity

Variantyx launched the Variantyx Unity test, a genomic diagnostic test that identifies small sequence changes, structural variants, trinucleotide repeat expansions, and mitochondrial variants from a single DNA sample. The test uses whole-genome seuqncing data analyzed by the firm's Genomic Intelligence platform, and eliminates the need for multiple sequential tests, the firm said. 

Sep 12, 2017

DiaSorin Molecular Simplexa C. difficile Direct Assay

DiaSorin Molecular has launched the Simplexa C. difficile Direct Assay in the US. The assay aids in the diagnosis of infection by detecting the C. difficile toxin B gene in liquid or unformed stool samples, and had been available outside the US since November. The US Food and Drug Administration cleared the test in February

Sep 12, 2017

Standard Diagnostics/Alere FIND SD Bioline HAT 2.0

Standard Diagnostics/Alere and FIND launched SD Bioline HAT 2.0, a rapid diagnostic test for human African trypanosomiasis, or sleeping sickness. The immunochromatographic rapid test detects antibodies against Trypanosoma brucei gambiense, the parasite that is responsible for more than 98 percent of sleeping sickness cases. The test can be performed by health workers with minimal training, using fresh blood from a finger prick, and results can be obtained in about 15 minutes. 

Sep 11, 2017

Perkinelmer QSight 210 MD system

PerkinElmer launched the QSight 210 MD system for routine high-throughput quantitation. The system includes tandem mass spectrometry technology, enabling laboratories to run hundreds of samples daily, the firm said, adding it provides a complete workflow from sample preparattion to end result. 

Sep 07, 2017

Bio-Techne Zika ELISA

R&D Systems, a Bio-Techne brand, launched a rapid solid phase enzyme-linked immunosorbent assay designed to measure anti-Zika virus immunoglobulin G antibodies in human serum. Samples are pre-treated with a proprietary reagent designed to minimize any interfering proteins present in the serum that could produce a false positive result. In-house testing demonstrates that this kit is highly sensitive to anti-Zika virus IgG and displays minimal cross-reactivity with dengue virus IgG antibodies, the firm said.

Sep 07, 2017

Eurofins Genoma GeneSafe

Eurofins Genoma has introduced GeneSafe, a non-invasive prenatal test that screens for both de novo and inherited single-gene disorders. Current commercial NIPTs only screen for aneuploidies and microdeletions, the firm said. GeneSafe identifies fetal conditions that could be missed by traditional prenatal testing, detecting more than 40 severe genetic disorders that may occur in the absence of a family history of the condition. The company said it also detects disorders with an increased prevalence associated with advanced paternal age. The test requires a small blood sample and has a turnaround time of 10 days. It works as a complementary screen to traditional NIPT, providing a more complete picture of the risk of a pregnancy being affected by a genetic disorder, the company noted.

Sep 07, 2017

Myriad Genetics riskScore

Myriad Genetics has launched riskScore, which employs a proprietary algorithm combining analysis of 80 SNPs and patients' personal and family history of cancer to determine a woman's risk of breast cancer. Results from this test will be reported alongside Myriad's myRisk Hereditary Cancer test, a 28-gene panel that gauges patients' risk for for eight cancers. RiskScore will help guide decisions for asymptomatic patients who get negative myRisk results, providing definitive answers to the 90 percent of patients testing negative for hereditary cancer genes, the company noted. Myriad has completed two validation studies in patients of European descent that it will present at upcoming conferences.

Sep 07, 2017

Intermountain Precision Genomics RxMatch

Intermountain Precision Genomics Core Laboratory launched RxMatch, a new service to enable physicians to implement personalized medicine when prescribing medications. The RxMatch Antidepressant Panel, launched Sept. 5 as part of the new service, will allow physicians to use patients' genomics to find the right antidepressant. The RxMatch Antidepressant Panel will be powered by CNSDose, a company that will provide decision support to Intermountain based on its knowledge of liver and blood-brain-barrier metabolism of antidepressant medications.

Sep 05, 2017

Meridian Life Science Tru Block Ultra

Meridian Life Science launched the Tru Block Ultra immunoassay interference blocker. The product employs blocking technology across a variety of assay types and blocks assay interference against human anti-mouse antiboidies, rheumatoid factor, and heterophilic antibodies. The company said that the blocking effectiveness of Tru Block Ultra has been proven in ELISA and lateral flow assay formats. 

Sep 05, 2017

Biocept NRAS Liquid Biopsy Test

Biocept has launched a new Target Selector liqud biopsy assay for mutations in the NRAS oncogene. According to the company, the NRAS mutations targeted by the test are associated with multiple cancer types such as metastatic melanoma, colorectal and lung cancer. The new test, like Biocept's other clinical assays, is run in its CLIA-certified San Diego lab. The new product brings the company's total number of Target Selector tests to 15.